tbuckley/cabot-search huggingface dataset:
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma
Authors: Francesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, Luca Laurenti, Giovanni Del Poeta, Gianluigi Reda, Marina Motta, Alessandro Gozzetti, Roberta Murru, Maria Denise Caputo, Melissa Campanelli, Anna Maria Frustaci, Idanna Innocenti, Sara Raponi, Anna Guarini, Fortunato Morabito, Robin Foà, Massimo Gentile
Journal: American Journal of Hematology (2017)

Abstract We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41‐80) and 70 years (range 46‐82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0‐258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) ≥4 in 50%, extranodal involvement in 39%, B symptoms in 70%. Prior treatment for CLL had been received by 82% of patients and included fludarabine in 67%. Coexistence of CLL and HL was detected in the same bioptic tissue in 87% of cases. The most common administered treatment was the ABVD regimen given to 22 patients (66.6%). The complete response (CR) rate after ABVD was 68%, and was influenced by the IPS ( P = .03) and interval from the last CLL treatment ( P = .057). Survival from HL was also influenced by the IPS ( P = .006) and time from the last CLL treatment ( P = .047). The achievement of CR with ABVD was the only significant and independent factor predicting survival ( P = .037). Taken together, our results show that the IPS and the interval from the prior CLL treatment influence the likelihood of achieving CR after ABVD, which is the most important factor predicting survival of patients with CLL developing HL.
Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry
Authors: Omri Avraham Arbiv, Bozana Zlateska, Robert J. Klaassen, Conrad Fernandez, Rochelle Yanofsky, John K. Wu, Nancy Robitaille, Mariana Silva, Jeffrey H. Lipton, Josee Brossard, Bruno Michon, Sharon Abish, MacGregor Steele, Roona Sinha, Mark J. Belletrutti, Vicky R. Breakey, Lawrence Jardine, Lisa Goodyear, Lillian Sung, Manju Wahala, Ibrahim A. Ghemlas, Hongbing Li, Michaela Cada, Yigal Dror
Journal: Blood (2015)
Risk of Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS): Results from a Population-Based Screening Study
Authors: Ebba K Lindqvist, Sigrun H Lund, Rene Costello, Debra Burton, Neha S Korde, Sham Mailankody, Magnus Björkholm, Gudny Eiriksdottir, Leonore J Launer, Tamara B Harris, Malin Hultcrantz, Vilmundur Gudnason, Ola Landgren, Sigurdur Y Kristinsson
Journal: Blood (2016)
Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.
Authors: Kai Neben, Leopold Sellner, Christiane Heiss, Axel Benner, Marc S Raab, Jens Hillengass, Dirk Hose, Nicola Lehners, Gerlinde Egerer, Anthony D Ho, Hartmut Goldschmidt
Journal: Blood (2012)
T Cells Expressing the Activating NK Cell Receptors KIR2DS4, NKG2C and NKG2D Are Elevated In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Cytotoxic towards Hematopoietic Progenitor Cell Lines
Authors: Sandra van Bijnen, Marian Withaar, Frank Preijers, Arnold van der Meer, Theo de Witte, Petra Muus, Harry Dolstra
Journal: Blood (2010)
Transfer of Cellular and Humoral Anti-Tumor Immunity with Immune T Cells After Stem Cell Transplant (SCT) for Metastatic Breast Cancer Following “Vaccination” with Anti-CD3 x Anti-Her2/Neu Bispecific Antibody (Her2Bi) Armed Activated T Cells
Authors: Archana Thakur, Zaid Al-Kadhimi, Cassara Pray, Elyse N. Tomaszewski, Ritesh Rathore, Patricia A. Steele, Muneer H. Abidi, Lois Ayash, Dana L Schalk, Karen Myers, Alice Mitchell, Abhinav Deol, Joseph P. Uberti, Voravit Ratanatharathorn, Lawrence G Lum
Journal: Blood (2011)
Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C
Authors: Maria Teresa Corsetti, Flavia Salvi, Sonia Perticone, Bernardino Allione, Anna Baraldi, Alessandro Bellora, Lorella De Paoli, Simona Gatto, Daniela Pietrasanta, Valeria Primon, Massimo Pini, Anna Tonso, Marco Musi, Giorgio Ciravegna, Francesco Zallio, Alessandro Levis
Journal: Blood (2008)
High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT).
Authors: Andrzej J. Jakubowiak, Ammar Al-Zoubi, Tara Kendall, Judah Friedman, Asra Ahmed, Yasser Khaled, Shin Mineishi, Mark S. Kaminski
Journal: Blood (2006)
<scp>NICE</scp> approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
Authors: J.R. Ingram, T. Burton
Journal: British Journal of Dermatology (2017)

Until very recently, hidradenitis suppurativa (HS) was largely ignored by medical regulators, the pharmaceutical industry and society in general. There were no formal HS guidelines, no licensed interventions for HS and no National Institute for Health and Care Excellence (NICE)‐approved treatments. In the U.K., Individual Patient Funding Requests to access biologic therapy for HS created delays and some requests were declined. Patients at the end of the financial year were potentially disadvantaged and access varied from region to region; the ad hoc model of funding was not a sustainable solution. Fortunately, the last couple of years have seen encouraging strides in HS patient care. We now have European S1 guidelines for HS and U.K. guidelines are under development.1 In 2015, adalimumab was approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, in the U.K., a cost‐effectiveness analysis by NICE is required for any new indication for an expensive intervention. Bearing in mind that the 40‐mg weekly licensed dose of adalimumab for HS is twice the dose for psoriasis and, back in 2015, twice the cost, an extensive analysis was undertaken.
Abstract PR05: Glycoprotein-mediated tissue mechanics regulate glioblastoma aggression
Authors: J. Matthew Barnes, Elliot C. Woods, Russell O. Bainer, Yekaterina A. Miroshnikova, Kan Lu, Gabriele Bergers, Carolyn Bertozzi, Valerie M. Weaver
Journal: Cancer Research (2017)

Abstract Glioblastoma multiforme (GBM) is a malignant glioma whose progression is associated with rampant extracellular matrix (ECM) remodeling. We recently found that GBM ECM stiffness predicts reduced survival in human patients. Instead of collagen fibrosis, which is common in many solid tumors, we showed that GBM stiffening involves increased production of extracellular glycoproteins, glycosaminoglycans, and sugar-binding proteins. Using bioinformatics, we revealed that genes of the glycocalyx (transmembrane glycoproteins and their interacting partners) are disproportionately upregulated in GBM relative to lower grade gliomas. Further, these genes are overexpressed within GBM in the mesenchymal (MES) relative to the proneural (PRO) subtype, the former of which is associated with treatment resistance and relapse. Using mouse models of human GBM, we showed that MES tumors are more lethal than PRO, and present with elevated ECM stiffness and mechanical signaling. To test our hypothesis that mechanical signaling can drive the MES phenotype, we engineered PRO GBM cells with constitutively-elevated integrin signaling. Compared to control PRO cells, these undergo a robust MES-like transition, upregulate bulky glycoprotein expression, and result in stiffer and more lethal tumors. This phenotype was reversed by the inhibition of focal adhesion kinase in MES cells. To test whether an enhanced glycocalyx can directly elevate mechanical signaling, we decorated GBM cells with synthetic glycoprotein polymers. Indeed, this resulted in enhanced integrin-focal adhesion signaling and more aggressive tumor progression. The invasive properties and therapy resistance observed in mesenchymal tumor cells are often associated with elevated stem cell-like features. To investigate a link between the glycocalyx, tissue mechanics, and the mesenchymal-stem cell phenotype, we interfered with components of the gylcocalyx or mechanical signaling machinery and found a reduction in stem cell genes and surface proteins, as well as increased sensitivity to chemotherapy. These data support a model in which glycoprotein-mediated tissue stiffening drives GBM aggression through promotion of a mesenchymal phenotype. This abstract is also being presented as Poster A39. Citation Format: J. Matthew Barnes, Elliot C. Woods, Russell O. Bainer, Yekaterina A. Miroshnikova, Kan Lu, Gabriele Bergers, Carolyn Bertozzi, Valerie M. Weaver. Glycoprotein-mediated tissue mechanics regulate glioblastoma aggression. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr PR05.
Discussion of Reports on Electrolyte and Adrenal Factors in Hypertension
Journal: Circulation (1958)

Dr. Findley reviewed his previous studies in which salt hyperexcretion in hypertension followed the pattern seen in adrenal hyperfunction and reemphasized the evidence for an unusual cellular change in the anterior pituitary gland in renal and renoprival hypertension. He reviewed work in progress in which he is attempting to reproduce Skelton's type of adrenal regeneration hypertension in dogs and puppies. Dr. Tobian reviewed the current status of his studies on electrolyte changes in the tissues in animals made hypertensive by various technics.
Prepared and Application of New Microarray-Based Method for Detecting SNP in the Risk of Hematological Malignancy.
Authors: Bao-An Chen, Ni Jiang, Mei-Ju Ji, Peng Hou, Zu-Hong Lu, Chong Gao, Jia-Hua Ding, Yun-Yu Sun, Jun Wang, Jian Cheng, Gang Zhao, Fei Fei, Ning-Na Chen
Journal: Blood (2005)
Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Authors: Qingyu Xu, Yan Li, Na Lv, Yu Jing, Yihan Xu, Yuyan Li, Wenjun Li, Zilong Yao, Xiaosu Chen, Sai Huang, Lili Wang, Yonghui Li, Li Yu
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Whether isocitrate dehydrogenase (IDH) gene aberrations affected prognosis of patients with acute myeloid leukemia (AML) was controversial. Here, we conducted a meta-analysis to evaluate their prognostic value. Experimental Design: PubMed, Embase, Cochrane, and Chinese databases were searched to identify studies exploring how IDH gene aberrations affected AML outcome. Pooled HRs and relative risks (RR) were calculated, along with 95% confidence intervals (CI). Results: Thirty-three reports were included. IDH mutations seemed not to affect overall survival (OS: HR, 1.05; 95% CI, 0.89–1.23) and event-free survival (EFS: HR, 0.97; 95% CI, 0.80–1.18) when considered as a single factor, but improved accumulative incidence of relapse (CIR: HR, 1.44; 95% CI, 1.18–1.76) in patients with intermediate-risk karyotypes (IR-AML). However, IDH1 mutation conferred worse OS (HR, 1.17; 95% CI, 1.05–1.31) and EFS (HR, 1.29; 95% CI, 1.07–1.56), especially in patients with normal cytogenetics (OS: HR, 1.21; 95% CI, 1.01–1.46; EFS: HR, 1.56; 95% CI, 1.23–1.98). Prognosis of the IDH1 single-nucleotide polymorphism rs11554137 was also poor (OS: HR, 1.34; 95% CI, 1.03–1.75). IDH2 mutation improved OS (HR, 0.78; 95% CI, 0.66–0.93), particularly in IR-AML patients (OS: HR, 0.65; 95% CI, 0.49–0.86). The IDH2 (R140) mutation was associated with better OS among younger cases (HR, 0.64; 95% CI, 0.49–0.82). Treatment outcome was poor [RR for complete remission rates in IDH1 mutation: 1.21; 95% CI, 1.02–1.44; IDH2 (R172) mutation: 2.14; 95% CI, 1.61–2.85]. Conclusions: Various subtypes of IDH mutations might contribute to different prognosis and be allowed to stratify IR-AML further. Clin Cancer Res; 23(15); 4511–22. ©2017 AACR.
Overexpression of BCL9, a Wnt/β-Catenin Transcriptional Co-Activator, in Transgenic Mice Promotes Spontaneous Development of B-Cell Malignancies
Authors: Tomasz Sewastianik, Jianjun Zhao, Meng Jiang, Peter S. Dennis, Myles Brown, Kwok Wong, Ruben D. Carrasco
Journal: Blood (2016)
Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study
Authors: Morten Schmidt, Kathryn E Mansfield, Krishnan Bhaskaran, Dorothea Nitsch, Henrik Toft Sørensen, Liam Smeeth, Laurie A Tomlinson
Journal: BMJ (2017)

Objective To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.Design Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.Setting UK primary care, 1997-2014.Participants Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).Main outcome measures Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. Analyses were adjusted for age, sex, calendar period, socioeconomic status, lifestyle factors, chronic kidney disease, diabetes, cardiovascular comorbidities, and use of other antihypertensive drugs and non-steroidal anti-inflammatory drugs.Results Among the 2078 (1.7%) patients with creatinine increases of 30% or more, a higher proportion were female, were elderly, had cardiorenal comorbidity, and used non-steroidal anti-inflammatory drugs, loop diuretics, or potassium sparing diuretics. Creatinine increases of 30% or more were associated with an increased adjusted incidence rate ratio for all outcomes, compared with increases of less than 30%: 3.43 (95% confidence interval 2.40 to 4.91) for end stage renal disease, 1.46 (1.16 to 1.84) for myocardial infarction, 1.37 (1.14 to 1.65) for heart failure, and 1.84 (1.65 to 2.05) for death. The detailed categorisation of increases in creatinine concentrations (<10%, 10-19%, 20-29%, 30-39%, and ≥40%) showed a graduated relation for all outcomes (all P values for trends <0.001). Notably, creatinine increases of less than 30% were also associated with increased incidence rate ratios for all outcomes, including death (1.15 (1.09 to 1.22) for increases of 10-19% and 1.35 (1.23 to 1.49) for increases of 20-29%, using <10% as reference). Results were consistent across calendar periods, across subgroups of patients, and among continuing users.Conclusions Increases in creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment were associated with adverse cardiorenal outcomes in a graduated relation, even below the guideline recommended threshold of a 30% increase for stopping treatment.
A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Bulky Stage II, Stage III or IV, Low-Grade B-Cell NHL.
Authors: Raul R. Mena, Neal P. Christiansen, Yudishtra Markan, Lalita Pandit
Journal: Blood (2006)
Erratum: Common variants at 6q22 and 17q21 are associated with intracranial volume
Authors: M Arfan Ikram, Myriam Fornage, Albert V Smith, Sudha Seshadri, Reinhold Schmidt, Stéphanie Debette, Henri A Vrooman, Sigurdur Sigurdsson, Stefan Ropele, H Rob Taal, Dennis O Mook-Kanamori, Laura H Coker, W T Longstreth, Wiro J Niessen, Anita L DeStefano, Alexa Beiser, Alex P Zijdenbos, Maksim Struchalin, Clifford R Jack, Fernando Rivadeneira, Andre G Uitterlinden, David S Knopman, Anna-Liisa Hartikainen, Craig E Pennell, Elisabeth Thiering, Eric A P Steegers, Hakon Hakonarson, Joachim Heinrich, Lyle J Palmer, Marjo-Riitta Jarvelin, Mark I McCarthy, Struan F A Grant, Beate St Pourcain, Nicholas J Timpson, George Davey Smith, Ulla Sovio, Mike A Nalls, Rhoda Au, Albert Hofman, Haukur Gudnason, Aad van der Lugt, Tamara B Harris, William M Meeks, Meike W Vernooij, Mark A van Buchem, Diane Catellier, Vincent W V Jaddoe, Vilmundur Gudnason, B Gwen Windham, Philip A Wolf, Cornelia M van Duijn, Thomas H Mosley, Helena Schmidt, Lenore J Launer, Monique M B Breteler, Charles DeCarli
Journal: Nature Genetics (2012)
Evolutionarily conserved serum microRNAs predict radiation-induced fatality in nonhuman primates
Authors: Wojciech Fendler, Beata Malachowska, Khyati Meghani, Panagiotis A. Konstantinopoulos, Chandan Guha, Vijay K. Singh, Dipanjan Chowdhury
Journal: Science Translational Medicine (2017)

Evolutionarily conserved serum microRNAs predict radiation-induced fatality in nonhuman primates.
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Authors: Ji Li, Nicola J. Stagg, Jennifer Johnston, Michael J. Harris, Sam A. Menzies, Danielle DiCara, Vanessa Clark, Maria Hristopoulos, Ryan Cook, Dionysos Slaga, Rin Nakamura, Luke McCarty, Siddharth Sukumaran, Elizabeth Luis, Zhengmao Ye, Thomas D. Wu, Teiko Sumiyoshi, Dimitry Danilenko, Genee Y. Lee, Klara Totpal, Diego Ellerman, Isidro Hötzel, John R. James, Teemu T. Junttila
Journal: Cancer Cell (2017)

The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion of CD45 phosphatase from the synapse. The dimensions of the target molecule play a key role in the efficiency of the synapse formation. The anti-FcRH5/CD3 TDB kills human plasma cells and patient-derived myeloma cells at picomolar concentrations and results in complete depletion of B cells and bone marrow plasma cells in cynomolgus monkeys. These data demonstrate the potential for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1 signaling, in the treatment of MM and other B cell malignancies.
Potential of Oncocardiology
Authors: Siew Lian Leong, Nathorn Chaiyakunapruk, Shaun Wen Huey Lee
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)
Authors: Matthew A. Cavender, William B. White, Petr Jarolim, George L. Bakris, William C. Cushman, Stuart Kupfer, Qi Gao, Cyrus R. Mehta, Faiez Zannad, Christopher P. Cannon, David A. Morrow
Journal: Circulation (2017)

We aimed to describe the relationship between changes in high-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.The EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) was a phase IIIb clinical outcomes trial designed to evaluate the cardiovascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor. Patients with type 2 diabetes mellitus, glycohemoglobin between 6.5% and 11% (or between 7% and 11% if they were on insulin), and a recent acute coronary syndrome (between 15 and 90 days before randomization) were eligible for the trial. hsTnI was measured using the Abbott ARCHITECT assay at baseline and 6 months in patients randomized in the EXAMINE trial. This analysis was restricted to patients randomized ≥30 days after qualifying acute coronary syndrome to mitigate the potential for persistent hsTnI elevation after acute coronary syndrome (n=3808). The primary end point of the trial was cardiovascular death, myocardial infarction, or stroke. Cardiovascular death or heart failure was a prespecified, adjudicated secondary end point.At baseline, hsTnI was detectable (≥1.9 ng/L) in 93% of patients and >99th percentile upper reference limit in 16%. There was a strong relationship between increasing hsTnI, both at baseline and 6 months, and the incidence of cardiovascular events through 24 months (P<0.001 for each). Patients with undetectable hsTnI at baseline and 6 months were at the lowest risk of future cardiovascular events. Stable patients with hsTnI ≥99th percentile upper reference limit at 6 months were at increased risk of cardiovascular death, myocardial infarction, or stroke compared with patients with hsTnI <99 percentile upper reference limit irrespective of whether hsTnI was newly elevated (28.1% versus 8.8%; adjusted hazard ratio, 2.65; 95% confidence interval, 1.64-4.28; P<0.001) or persistently so (22.5% versus 8.8%; adjusted hazard ratio, 1.90; 95% confidence interval, 1.33-2.70; P<0.001). Alogliptin neither increased nor decreased the risk of cardiovascular events compared with placebo in patients with high baseline hsTnI (22.3% versus 23.0%; hazard ratio, 0.87; 95% confidence interval, 0.60-1.25; P=0.44).Serial assessment of hsTnI revealed a substantial proportion of patients with type 2 diabetes mellitus without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes mellitus based on risk.URL: http://www.clinicaltrials.gov. Unique identifier: NCT00968708.
Contents, Vol. 55, 1991
Authors: A.J.J.M. Vingerhoets, J. Assies, E. Heim, Raimo K.R. Salokangas, Matti Joukamaa, George N. Christodoulou, Z.J. Lipowski, Bengt B. Arnetz, Sten-Olof Brenner, Lennart Levi, Robert Hjelm, Inga-Lill Petterson, Jerzy Wasserman, Björn Petrini, Peter Eneroth, Anders Kallner, Richard Kvetnansky, Milan Vigas, Tores Theorell, E.M. Wekking, A.J.J.M. Vingerhoets, A.P. van Dam, J.C. Nossent, A.J.J.G. Swaak, Giovanni A. Fava, Silvana Grandi, Vappu Viemerö, E.M. Wekking, J.C. Nossent, A.P. van Dam, A.J.J.G. Swaak, A.P. van Dam, E.M. Wekking, H.A.P.C. Oomen, Laurens D. Young, Jan Schweiger, Jan Beitzinger, Robert McManus, Carolyn Bloedel, J. Koob, Carl-Erik Mattlar, Erik Engblom, Päivi Vesala, Esko Vänttinen, Lars-Runar Knuts, C. Buddeberg, C. Wolf, M. Sieber, A. Riehl-Emde, A. Bergant, R. Steiner, C. Landolt-Ritter, D. Richter, R.P.W. Fry, A.H. Crisp, R.W. Beard, Richard Petty, Tom Sensky, Robert Mahler, Kirsteen Stevenson, Tom Sensky, Richard Petty, Alf Forsén, Matti Joukamaa, Argyro Voulgari, Lefteris Lykouras, Metaxia Papanikolaou, Anastasia Tzonou, Aekaterini Danou-Roussaki, George Christodoulou, Bengt B. Arnetz
Journal: Psychotherapy and Psychosomatics (1991)